EXECUTIVE COMMENTARY Ian Read
Pfizer · USA
Track record: No forecast checked yet (0 not due, 4 being checked).
4forecasts & commitments on the record
50%can be checked as stated
32average ambiguity (0-100)
0goalpost moves recorded
0confirmed U-turns
Timeline
came true partly did not not due / being checked / too vague
Calibration score: shown after 10 checked forecasts with a stated likelihood (now 0).
How they speak about the future: based on data 4.
Kinds of claim: forecast 4.
In the nine words
How to read this
Each box is one sentence a public figure or institution said about the future, word for word, with a link to the official text. Can be checked means it names what will happen, by when, and how likely - so it can be compared with official figures later. Too vague to check means it does not. Ambiguity (0-100) is how many different ways the sentence can be read. When the date passes, the forecast is compared with official data and marked came true, partly or did not come true. Labels judge the sentence, never the person. Full guide and glossary.On the record (4)
“Earlier this month, we announced that Albert Bourla will succeed me as CEO starting in January 2019.
The new structure is a natural evolution of our business as we transition to a period post-2020 where we expect a higher and more sustained revenue growth profile driven by this new structure, the ongoing success of our in-market products, our advancing pipeline and a dramatic reduction in loss of exclusivity impacts,
Over the next five years, we project the potential for approximately 25 to 30 approvals of which up to 15 have the potential to be blockbusters, and we believe half of these potential blockbusters could receive approval by 2020.
“In addition, we have made excellent progress integrating the legacy Hospira operations and now expect to achieve $1.0 billion of Hospira cost savings by 2018, 25% more than our initial cost savings target of $800 million.
Also said - not checkable as stated (4 newest)
Remarks about the future with no date, figure or likelihood that could be checked. They are kept on the record and shown here, but not scored.
I am confident that he is implementing a structure and building a leadership team that will maximize the company’s growth opportunities,
“Finally, we will continue to allocate our capital to initiatives that we believe will maximize value creation,
With continued strength in emerging markets, the sterile injectables business and the biosimilars portfolio, we anticipate the Essential Health business will be able to transition to a modest revenue growth business on an overall portfolio basis.
“I believe that we are well positioned to deliver another strong year in 2016 as we expect that our key in-line products will continue to perform well while we expect to advance our product pipeline, notably our potential registrational programs in key therapeutic areas such as oncology, vaccines, cardiovascular and metabolic diseases, inflammation and rare diseases.